Join our daily newsletter At The Bell to receive exclusive market insights
- Biotech company dorsaVi has been granted a U.S. patent for its sensor technology
- The ‘measuring reaction forces’ patent has already been granted in Australia and China
- It will aim to protect dorsaVi’s device and the method that allow the sensor to work
- Despite this news, dorsaVi is down 11.8 per cent with shares trading for 3 cents apiece
Biotech company dorsaVi has been granted a U.S. patent for its sensor technology, which further strengthens its intellectual property.
The ‘measuring reaction forces’ patent has already been granted in Australia and China.
It not only protects dorsaVi’s technologies, but allows the company to continue to evolve its products and maintain its global leadership position in medical grade wearables.
The U.S. Patent & Trademark Office has issued a Notice of Allowance for dorsaVi’s patent application, Apparatus and method for measuring reaction forces.
This patent protects the apparatus (the sensors) and also the method (the algorithms) that allow dorsaVi’s sensor technology to determine the reaction force of the limb contacting the ground or surface that the person in walking on.
This is an important component when assessing whether certain movements are associated with a higher risk of causing or contributing to an injury.
The data is relevant for dorsaVi customers in the workplace, sports and clinical markets.
The patent has a 20 year term and will expire on July 24, 2033.
dorsaVi’s technology is applicable across three sectors, clinical, elite sports and occupational health and safety (OHS).
Its ViMove, ViMove2, and Professional Suite, for clinical use, provides objective assessment, monitoring outside of the clinic and immediate biofeedback.
dorsaVi is currently used by medical and physiotherapy practices globally.
In elite sports dorsaVi’s ViPerform allows coaches and medical teams to screen athletes and provide objective evidence for decisions on return to play, provide immediate biofeedback on the field, and tailor and track training programs.
ViPerform is currently being used in the U.S. by the National Basketball Association, the Major Soccer League, and the National Football League.
In Australia it’s being used by the AFL, NRL, Cricket Australia, and the Australian Institute of Sport.
For OHS, dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment and methods.
It has been used by big name companies such as Coles, Woolworths, Crown Resorts, Toyota, BHP Billiton, and Caterpillar in the U.S.
Despite this news, dorsaVi is down almost 12 per cent today with shares trading for 3 cents apiece at 2:55 pm AEDT.
